Lemieux J, et al. - In Canadian Cancer Trials Group MA.17R, researchers compared letrozole to placebo after 5 years of aromatase inhibitor as adjuvant therapy for hormone receptor–positive breast cancer. Here researchers reported the outcomes related to quality of life (QOL), a secondary outcome measure of the study. Observations revealed no clinically significant differences regarding overall QOL between the letrozole and placebo groups. Data suggested no deterioration of overall QOL in relation to the continuation of aromatase inhibitor therapy after 5 years of prior treatment in the trial population.